Danny Williams

EVERSANA's Danny Williams on how cell and gene therapies, AI, and direct-to-patient fulfillment are reshaping the pharma 3PL model.

Danny Williams breaks down direct-to-patient distribution and his outlook on where pharma 3PLs are headed over the next five years.

Danny Williams discusses how AI has moved from experimental pilots to full operational deployment across supply chain functions, and how cell and gene therapies are reshaping the logistics industry.

EVERSANA's Danny Williams breaks down the most consequential operational shifts in pharma 3PL over the past five years, from full-pallet distribution to integrated commercialization support for complex, targeted therapies.